North America holds the largest market share, accounting for 40% of the global total. This dominance is driven by advanced healthcare infrastructure, high healthcare spending, a strong presence of leading pharmaceutical and medical device companies, and a significant focus on neonatal care in the United States.
Key growth drivers include the rising global incidence of preterm births, continuous advancements in neonatal care technologies (such as sophisticated respiratory support systems), and increasing awareness among healthcare providers and parents leading to earlier interventions.
Hospitals currently dominate the market, accounting for approximately 60% of the total share. This leadership is attributed to the presence of advanced neonatal intensive care units (NICUs) and specialized pediatric departments. However, the "Clinic" sub-segment is projected to be the fastest-growing due to the rise in outpatient care options.
The market faces several hurdles, including a lack of currently approved specific therapies, a high number of undiagnosed cases due to limited awareness in certain regions, and inconsistent diagnostic criteria across clinical studies, which creates uncertainty in market forecasting.
In December 2024, Oak Hill Bio initiated a clinical trial for OHB-607, a new investigational drug. Additionally, in April 2021, the FDA approved Airway Therapeutics’ IND application for AT-100, a preventive treatment option for BPD in vulnerable newborns.
Researchers are increasingly focusing on tailoring BPD treatments to individual genetic profiles. This shift toward personalized medicine allows for targeted therapies that improve patient outcomes while reducing potential side effects, making neonatal care safer and more effective.
The Asia Pacific region is witnessing rapid growth, led by countries such as China, India, and Japan. This is fueled by rising birth rates, expanding neonatal healthcare systems, and increasing government support for maternal and child health programs.
AI and machine learning tools are becoming vital for early diagnosis and the development of optimized treatment plans. These technologies help clinicians catch BPD signs faster and analyze complex data to improve long-term results for preterm infants.
Prominent market players include Chiesi Farmaceutici S.p.A., AbbVie Inc., Mallinckrodt Pharmaceuticals, AstraZeneca plc, Pfizer Inc., and GlaxoSmithKline plc. Other emerging companies developing novel drugs include Oak Hill Bio, Airway Therapeutics, Windtree Therapeutics, and Trimunocor.
